Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 5/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | VDR | P11473 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | CYP24A1 | Q07973 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | CA9 | Q16790 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10880588 | 0.85 | KEAP1 (0.39) | KEAP1NFE2L2VDRHTTSMN1; SMN2 | |
| SCHEMBL955492 | 0.85 | CYP2C19 (0.43) | KEAP1NFE2L2VDRHTTSMN1; SMN2 | |
| SCHEMBL6004113 | 0.85 | ENPP3 (0.42) | HTTSMN1; SMN2CA12CA9CA1 | |
| SCHEMBL10879744 | 0.83 | MEN1 (0.38) | KEAP1NFE2L2VDRHTTSMN1; SMN2 | |
| SCHEMBL10248678 | 0.82 | STAT3 (0.38) | KEAP1NFE2L2VDRHTTSMN1; SMN2 | |
| SCHEMBL28719294 | 0.81 | CYP24A1 (0.42) | KIF11VDRHTTSMN1; SMN2STAT3 | |
| SCHEMBL22945668 | 0.80 | CYP24A1 (0.41) | KIF11VDRHTTSMN1; SMN2STAT3 | |
| SCHEMBL1502260 | 0.80 | STAT3 (0.44) | KEAP1NFE2L2VDRSTAT3CA12 | |
| SCHEMBL6002078 | 0.80 | ALDH1A1 (0.43) | KEAP1NFE2L2VDRSTAT3CA12 | |
| SCHEMBL31516447 | 0.80 | TK1 (0.46) | KIF11VDRHTTSMN1; SMN2STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287298-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | ALLELIX NEUROSCIENCE INC. | 2006-12-21 | — | — | US | disclosed |
| EP-1014966-B1 | PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | ALLELIX NEUROSCIENCE INC (US) | 2006-08-02 | — | — | EP | disclosed |
| US-7019024-B2 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | ALLELIX NEUROSCIENCE INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-6191165-B1 | ANTIDEPRESSANTS; SCHIZOPHRENIA; ALZHEIMER'S DISEASE; ANTIEPILEPTIC AGENTS | ALLELIX NEUROSCIENCE INC. | 2001-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287298-A1 | Pharmaceutical for treatment of neurological and neuropsychiatric disorders | SLC18A2, SLC6A1, SLC6A11 | KIF11 407/4885KEAP1 445/4885NFE2L2 1948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.